WallStreetZenWallStreetZen

NASDAQ: DARE
Dare Bioscience Inc Stock Forecast, Predictions & Price Target

Open Broker Account

Analyst price target for DARE

Based on 1 analyst offering 12 month price targets for Dare Bioscience Inc.
Min Forecast
$6.00+506.06%
Avg Forecast
$6.00+506.06%
Max Forecast
$6.00+506.06%

Should I buy or sell DARE stock?

Based on 1 analyst offering ratings for Dare Bioscience Inc.
Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their DARE stock forecasts and price targets.

DARE stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
HC Wainwright & Co.
Top 19%
82
BuyMaintains$6.00+506.06%2022-04-01

1 of 1

Forecast return on equity

Is DARE forecast to generate an efficient return?
Company
74.46%
Industry
22.46%
Market
122.06%
DARE's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is DARE forecast to generate an efficient return on assets?
Company
47.86%
Industry
13.57%
DARE is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

DARE earnings per share forecast

What is DARE's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.30
Avg 2 year Forecast
-$0.37
Avg 3 year Forecast
-$0.19

DARE revenue forecast

What is DARE's revenue in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
$18.1M+81.26%
Avg 2 year Forecast
$20.8M+107.5%
Avg 3 year Forecast
$35.1M+250.83%
DARE's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

DARE revenue growth forecast

How is DARE forecast to perform vs Biotechnology companies and vs the US market?
Company
49.81%
Industry
23.83%
Market
8.53%
DARE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
DARE's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

DARE vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
DARE$0.99$6.00+506.06%Buy
OCX$0.71$2.20+209.86%Buy
ELYM$3.18$4.00+25.79%Buy
NXTC$3.00$14.50+383.33%Strong Buy
EYEN$2.43$12.00+393.83%Buy

Dare Bioscience Stock Forecast FAQ

Is Dare Bioscience Stock a good buy in 2022, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NASDAQ: DARE) stock is to Buy DARE stock.

Out of 1 analyst, 0 (0%) are recommending DARE as a Strong Buy, 1 (100%) are recommending DARE as a Buy, 0 (0%) are recommending DARE as a Hold, 0 (0%) are recommending DARE as a Sell, and 0 (0%) are recommending DARE as a Strong Sell.

If you're new to stock investing, here's how to buy Dare Bioscience stock.

What is DARE's earnings growth forecast for 2022-2024?

(NASDAQ: DARE) Dare Bioscience's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 8.86%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 16.88%.

Dare Bioscience's earnings in 2022 is -$30,194,382.On average, 3 Wall Street analysts forecast DARE's earnings for 2022 to be -$25,446,257, with the lowest DARE earnings forecast at -$31,383,717, and the highest DARE earnings forecast at -$19,508,797. On average, 3 Wall Street analysts forecast DARE's earnings for 2023 to be -$31,383,717, with the lowest DARE earnings forecast at -$42,410,429, and the highest DARE earnings forecast at -$17,812,380.

In 2024, DARE is forecast to generate -$16,115,963 in earnings, with the lowest earnings forecast at -$33,080,135 and the highest earnings forecast at -$6,785,669.

What is DARE's revenue growth forecast for 2022-2024?

(NASDAQ: DARE) Dare Bioscience's forecast annual revenue growth rate of 49.81% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 23.83%, and and it is also forecast to beat the US market's average forecast revenue growth rate of 8.53%.

Dare Bioscience's revenue in 2022 is $10,000,000.On average, 3 Wall Street analysts forecast DARE's revenue for 2022 to be $1,537,462,872, with the lowest DARE revenue forecast at $848,208,580, and the highest DARE revenue forecast at $2,615,875,261. On average, 2 Wall Street analysts forecast DARE's revenue for 2023 to be $1,760,032,804, with the lowest DARE revenue forecast at $448,702,339, and the highest DARE revenue forecast at $3,071,363,268.

In 2024, DARE is forecast to generate $2,975,770,161 in revenue, with the lowest revenue forecast at $687,048,950 and the highest revenue forecast at $4,872,958,292.

What is DARE's forecast return on assets (ROA) for 2022-2025?

(NASDAQ: DARE) forecast ROA is 47.86%, which is higher than the forecast US Biotechnology industry average of 13.57%.

What is DARE's Price Target?

According to 1 Wall Street analyst that have issued a 1 year DARE price target, the average DARE price target is $6.00, with the highest DARE stock price forecast at $6.00 and the lowest DARE stock price forecast at $6.00.

The Wall Street analyst predicted that Dare Bioscience's share price could reach $6.00 by Apr 1, 2023. The average Dare Bioscience stock price prediction forecasts a potential upside of 506.06% from the current DARE share price of $0.99.

What is DARE's Earnings Per Share (EPS) forecast for 2022-2024?

(NASDAQ: DARE) Dare Bioscience's current Earnings Per Share (EPS) is -$0.46. On average, analysts forecast that DARE's EPS will be -$0.30 for 2022, with the lowest EPS forecast at -$0.37, and the highest EPS forecast at -$0.23. On average, analysts forecast that DARE's EPS will be -$0.37 for 2023, with the lowest EPS forecast at -$0.50, and the highest EPS forecast at -$0.21. In 2024, DARE's EPS is forecast to hit -$0.19 (min: -$0.39, max: -$0.08).

What is DARE's forecast return on equity (ROE) for 2022-2025?

(NASDAQ: DARE) forecast ROE is 74.46%, which is considered strong.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.